J&J's medical device sales fall short, cancer drugs seen growing
Recasts with focus on medical device sales miss, Adds investor call details in paragraphs 8-10 and 17, updates shares
By Patrick Wingrove and Bhanvi Satija
April 16 (Reuters) -Johnson & Johnson's JNJ.N first-quarter revenue missed Wall Street estimates for medical devices on Tuesday and sales of its blockbuster psoriasis drug Stelara came in lower than expected as the company prepares for its loss of exclusivity in the U.S.
J&J's large medical devices business reported $7.82 billion in sales for the quarter, boosted by strong demand for Abiomed heart pumps and devices used in wound closure surgeries.
That was still short of analysts' estimates of $7.88 billion. Two analysts pointed to a weakness in J&J's vision care products and surgical devices.
"China-related issues seemed to play a restraining role in both divisions' underperformance," said Stifel analyst Rick Wise.
J&J shares were down 1.3% at $145.71. Shares of other medical device makers Zimmer Biomet ZBH.N, Stryker SYK.N and Medtronic MDT.N were also down about 1%
Sales of Carvykti, a cell therapy cancer treatment that analysts expect to bring in $1.15 billion this year, was $157 million for the quarter, missing Wall Street estimates of $200 million.
Supply has been a constraint on Carvykti sales, Wolk said, but added that the company was working with the U.S. FDA to enable increased capacity at its plants in New Jersey and Belgium.
J&J has doubled its manufacturing capacity for cell processing since 2023, a company executive said on an investor call. The drugmaker expects sales of Carvykti to continue to grow this year, particularly in the second half, as it expands capacity.
Sales of cancer drug Darzalex jumped 19% to $2.69 billion, about in line with expectations. The multiple myeloma treatment is expected to bring in sales of more than $11 billion this year, according to analysts.
Stelara sales were flat at $2.45 billion, falling short of analysts' expectations of $2.6 billion, according to LSEG data.
J&J Chief Financial Officer Joe Wolk said Stelara revenue was flat because of contracting with healthcare providers and pharmacy benefit managers in anticipation of the drug's loss of exclusivity in the U.S. next year.
"We probably expect this year to be flattish, maybe a little bit up in the United States, as we prepare for some contracts to preserve volume, but maybe give a little bit on price for the longer term," Wolk said.
J&J has struck deals to delay U.S. launches of biosimilars, or close copies, of Stelara until 2025, after a key patent expired last year.
Analysts have said the delayed competition will make the drug a larger contributor for J&J's 2024 and 2025 revenue than previously anticipated.
Stelara biosimilars are expected to launch elsewhere later this year. J&J reached an agreement with Alvotech ALVO.O in February to launch its version in Japan, Canada and Europe this year. The Luxembourg-based drugmaker began selling the medicine in Canada last month under the name Jamteki and can launch in Japan in May.
'SIGNIFICANT FLEXIBILITY' FOR DEALS
J&J announced this month that it had agreed to buy Shockwave Medical SWAV.O for $13.1 billion to acquire its device that uses vibrations to break down calcium deposits in heart vessels.
Wolk said operational growth in medical devices this quarter - up 6.3% from the year-ago quarter - "probably speaks to why we were seeking to add to that portfolio with the potential acquisition of Shockwave."
CEO Joaquin Duato said the company was still in the market for deals or acquisitions. "We have significant flexibility to consider multiple types of transactions," he said on the investor call.
On an adjusted basis, J&J earned $2.71 per share in the first quarter, beating estimates 7 cents. It reported total revenue of $21.38 billion, shy of estimates of $21.40 billion.
J&J raised the low end of its 2024 forecast by 5 cents and now expects an adjusted profit of $10.60 to $10.75 per share.
It also increased its quarterly dividend by 4.2% to $1.24 per share.
Sales of J&J's top selling treatments https://reut.rs/3Q30NA2
Reporting by Bhanvi Satija and Mariam Sunny in Bengaluru and Patrick Wingrove in New York; Editing by Shounak Dasgupta and Bill Berkrot
İlgili varlıklar
En son haberler
Bildirim: XM Group şirketlerinin her biri yalnızca gerçekleştirme hizmeti ve online yatırım platformumuza erişim sağlar. Herhangi bir kişinin web sitesinde bulunan veya web sitesi üzerinden sağlanan içeriği görüntülemesine ve/veya kullanmasına izin vermek, bu hizmeti değiştirmek veya genişletmek amaçlı değildir ve bu hizmeti ne değiştirir ne de genişletir. Bu tür erişim ve kullanım her zaman şunlara tabidir: (i) Şartlar ve Koşullar; (ii) Risk Uyarıları ve (iii) Tam Bildirim. Bu nedenle bu tür içerikler yalnızca genel bilgi amacıyla sağlanır. Özellikle, online yatırım platformumuzun içeriklerinin finans piyasalarında herhangi bir işleme girmek için bir teşvik veya bir teklif olmadığını lütfen dikkate alın. Herhangi bir finans piyasasında yatırım yapmak sermayeniz için önemli düzeyde risk taşır.
Online yatırım platformumuzda yayınlanan tüm materyaller yalnızca eğitim/bilgilendirme amaçlıdır ve finansal tavsiye, yatırım vergisi veya yatırım tavsiyesi ve önerileri ya da yatırım fiyatlarımızın kaydı veya herhangi bir finansal enstrümanda işlem yapılması için bir teklif veya teşvik ya da talep edilmemiş finansal promosyonları içermez ve içerdiği şeklinde bir değerlendirme yapılmamalıdır.
Görüşler, haberler, araştırma, analizler, fiyatlar, diğer bilgiler veya bu web sitesinde bulunan üçüncü taraf sitelere verilen bağlantılar gibi her türlü üçüncü taraf içeriğin yanı sıra XM tarafından hazırlanan içerik de “olduğu gibi” esasına göre, genel piyasa yorumu olarak sağlanır ve bir yatırım tavsiyesi oluşturmaz. Herhangi bir içeriğin yatırım araştırması olarak yorumlanmasıyla ilgili olarak, içeriğin bağımsız yatırım araştırmasını desteklemek üzere tasarlanmış yasal gerekliliklere uygun hazırlanmadığını ve bu amacın güdülmediğini, aynı şekilde ilgili yasalar ve mevzuatlar kapsamında pazarlama iletişimi olarak değerlendirileceğini dikkate almalı ve kabul etmelisiniz. Buradan erişebileceğiniz Bağımsız Olmayan Yatırım Araştırması Bildirimimizi ve yukarıdaki bilgilerle ilgili Risk Uyarımızı okuduğunuzdan ve anladığınızdan emin olun.
